Microba Life Sciences (ASX:MAP) NonCurrent Deferred Liabilities: A$1.80 Mil (As of Dec. 2025)


What is Microba Life Sciences NonCurrent Deferred Liabilities?

Microba Life Sciences ASX:MAP +2.50% NonCurrent Deferred Liabilities is A$1.80 Mil as of Dec. 2025. The stock has 6 warning signs investors should review.

Non-Current Deferred Liabilities represents the non-current portion of obligations, which is a liability that usually would have been paid but is now pas due.

Microba Life Sciences's non-current deferred liabilities for the quarter that ended in Dec. 2025 was A$1.80 Mil.

Microba Life Sciences NonCurrent Deferred Liabilities Related Terms

Microba Life Sciences NonCurrent Deferred Liabilities Historical Data

* Premium members only.

The historical data trend for Microba Life Sciences's NonCurrent Deferred Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Microba Life Sciences NonCurrent Deferred Liabilities Chart

Microba Life Sciences Annual Data
Trend Jun22 Jun23 Jun24 Jun25
NonCurrent Deferred Liabilities
0.00 0.00 1.57 2.17

Microba Life Sciences Semi-Annual Data
Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
NonCurrent Deferred Liabilities Get a 7-Day Free Trial Premium Member Only 0.00 1.57 2.21 2.17 1.80
What does a NonCurrent Deferred Liabilities of A$1.80 Mil mean?
Microba Life Sciences (ASX:MAP) has a NonCurrent Deferred Liabilities of A$1.80 Mil as of Dec. 2025. Non-current deferred liabilities represent the company obligations not paid yet not due within the current period. View historical data on Microba Life Sciences and its competitors.
Is Microba Life Sciences' NonCurrent Deferred Liabilities too high?
Microba Life Sciences' current NonCurrent Deferred Liabilities is A$1.80 Mil.
How does Microba Life Sciences' NonCurrent Deferred Liabilities compare to TMO and DHR?
Microba Life Sciences' NonCurrent Deferred Liabilities of A$1.80 Mil can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good NonCurrent Deferred Liabilities for a Medical Diagnostics & Research company?
A good NonCurrent Deferred Liabilities depends on the Medical Diagnostics & Research industry context. However, NonCurrent Deferred Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high NonCurrent Deferred Liabilities mean?
A high NonCurrent Deferred Liabilities can signal that a stock is expensive relative to its fundamentals. Non-current deferred liabilities represent the company obligations not paid yet not due within the current period. View historical data on Microba Life Sciences and its competitors. Microba Life Sciences's current NonCurrent Deferred Liabilities is A$1.80 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Microba Life Sciences stock overvalued right now?
Based on GuruFocus' analysis, Microba Life Sciences (ASX:MAP) is currently considered Possible Value Trap. The stock's GF Value™ is A$0.25, compared to a current price of A$0.04 — trading 83.6% below its estimated fair value. The current NonCurrent Deferred Liabilities is A$1.80 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is NonCurrent Deferred Liabilities calculated?
NonCurrent Deferred Liabilities is calculated from a company's financial statements. For Microba Life Sciences (ASX:MAP), the current NonCurrent Deferred Liabilities is A$1.80 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Microba Life Sciences Business Description

Address 324 Queen Street, Level 10, Brisbane, QLD, AUS, 4000
Microba Life Sciences Ltd is a commercial-stage company with technology for measuring the human gut microbiome and engages in providing gut microbiome testing services globally to consumers, clinicians, and researchers. It is also involved in developing new pathology services, therapeutics, and diagnostics based on the human gut microbiome. The company's operating segments are: Testing Services and Supplements, which derive key revenue, and Research and Development. Geographically, the company derives maximum revenue from Australia and the rest from Europe, New Zealand, the United States, Asia, and other regions.